Table 2.
Univariable and multivariable analysis of prognostic factors.
| Variables† | Recurrence-Free Survival | Overall Survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable Analysis | Multivariable Analysis | Univariable Analysis | Multivariable Analysis | |||||||||
| HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age [ ≤ 60 years] | 0.842 | 0.630–1.125 | 0.245 | 0.803 | 0.573–1.126 | 0.204 | ||||||
| Sex [man] | 0.989 | 0.666–1.468 | 0.956 | 0.884 | 0.539–1.450 | 0.626 | ||||||
| HBsAg [−] | 0.570 | 0.318–1.025 | 0.060 | 0.351 | 0.143–0.857 | 0.022* | 0.432 | 0.173–1.081 | 0.079 | |||
| Tumor size [2–3 cm] |
1.461 | 1.099–1.942 | 0.009* | 1.526 | 1.140–2.044 | 0.005* | 1.544 | 1.108–2.150 | 0.010* | 1.715 | 1.217–2.416 | 0.002* |
| Tumor number [1] | 1.655 | 1.239–2.211 | 0.001* | 1.485 | 1.092–2.011 | 0.015* | 1.864 | 1.337–2.599 | < 0.001* | 1.744 | 1.181–2.590 | 0.004* |
| PLT [ ≤ 100 × 109/L] | 2.245 | 1.139–4.423 | 0.019* | 2.296 | 1.151–4.582 | 0.018* | 3.223 | 1.562–6.652 | 0.002* | 3.563 | 1.665–7.625 | 0.001* |
| ALB [ ≤ 35 g/L] | 1.302 | 0.980–1.731 | 0.069 | 1.578 | 1.136–2.192 | 0.007* | 0.863 | 0.529–1.410 | 0.557 | |||
| ALT [ ≤ 40 U/L] | 1.016 | 0.756–1.367 | 0.914 | 1.124 | 0.800–1.579 | 0.499 | ||||||
| TBIL [ ≤ 20.5 μmol/L] | 1.422 | 1.041–1.941 | 0.027* | 1.183 | 0.847–1.653 | 0.324 | 1.130 | 0.795–1.608 | 0.495 | |||
| Prothrombin activity [ ≤ 70%] | 1.277 | 0.957–1.702 | 0.097 | 1.592 | 1.146–2.212 | 0.006* | 1.579 | 0.966–2.580 | 0.068 | |||
| AFP [≤ 400 μg/L] |
1.886 | 1.413–2.516 | < 0.001* | 2.150 | 1.587–2.911 | < 0.001* | 2.172 | 1.559–3.027 | < 0.001* | 2.287 | 1.615–3.238 | < 0.001* |
| Tumor stage of primary HCC [BCLC A] | 1.105 | 0.748–1.633 | 0.615 | 1.150 | 0.736–1.798 | 0.539 | ||||||
| Interval of recurrence from initial treatment [ ≤ 1 year] | 0.658 | 0.493–0.879 | 0.005* | 0.641 | 0.465–0.883 | 0.006* | 0.650 | 0.466–0.909 | 0.012* | 0.728 | 0.497–1.068 | 0.104 |
| Initial hepatic resection type [one segment] | 1.076 | 0.807–1.434 | 0.618 | 1.347 | 0.970–1.871 | 0.076 | ||||||
| Antiviral treatment for hepatitis B [yes] | 0.886 | 0.644–1.218 | 0.455 | 0.862 | 0.592–1.253 | 0.436 | ||||||
| MVI grade [M1] | 1.512 | 1.136–2.012 | 0.005* | 1.695 | 1.251–2.295 | 0.001* | 1.528 | 1.099–2.126 | 0.012* | 1.623 | 1.111–2.139 | 0.007* |
| Treatment allocation [combination therapy] | 1.749 | 1.315–2.325 | < 0.001* | 1.956 | 1.439–2.658 | < 0.001* | 1.670 | 1.199–2.327 | 0.002* | 1.636 | 1.129–2.370 | 0.009* |
*Statistically significant at alpha = 0.05. †Data in square brackets is the reference.
HR, hazard ratio; CI, confidence interval; HBsAg, hepatitis B surface antigen; PLT, platelet; ALB, albumin; ALT, alanine aminotransferase; TBIL, total bilirubin; AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer group; MVI, microvascular invasion.